This publication describes the study used to identify digital biomarkers that predict performance on gold standard neurocognitive tests.
RELATED CONTENT: Behind the Paper. This accompanying article describes the story behind Mindstrong’s technology, and the journey Paul Dagum, Founder and CEO, took to develop the pioneering concept and work.
This poster reports preliminary results from a Phase 2A trial of BTRX-246040, a potent and selective antagonist of the human nociception receptor (NOPR), as a treatment for anhedonia in patients with major depressive disorder. Mindstrong’s digital phenotyping is one of the outcome measures being used to assess efficacy.
This Commentary describes the changing ecosystem as small and large tech companies become involved in biomedical research and healthcare.